Humankind Investments LLC Has $502,000 Position in Cencora, Inc. (NYSE:COR)

Humankind Investments LLC lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 4.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,233 shares of the company’s stock after purchasing an additional 88 shares during the quarter. Humankind Investments LLC’s holdings in Cencora were worth $502,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the stock. JFS Wealth Advisors LLC lifted its stake in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after acquiring an additional 46 shares during the last quarter. Banque Transatlantique SA bought a new position in Cencora during the 4th quarter worth approximately $29,000. SBI Securities Co. Ltd. bought a new position in Cencora during the 4th quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC boosted its stake in shares of Cencora by 85.2% in the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares during the last quarter. Finally, Kentucky Trust Co acquired a new stake in shares of Cencora during the fourth quarter worth $33,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Cencora

In other news, Chairman Steven H. Collis sold 14,579 shares of the business’s stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $281.81, for a total value of $4,108,507.99. Following the transaction, the chairman now owns 315,913 shares in the company, valued at $89,027,442.53. The trade was a 4.41 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the sale, the executive vice president now directly owns 15,374 shares of the company’s stock, valued at $3,724,197.76. The trade was a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,223 shares of company stock valued at $13,580,967 over the last ninety days. Corporate insiders own 10.80% of the company’s stock.

Cencora Trading Down 0.2 %

COR opened at $283.12 on Friday. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $309.35. The firm has a market capitalization of $54.90 billion, a PE ratio of 40.27, a P/E/G ratio of 1.31 and a beta of 0.60. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The company’s 50-day moving average is $276.48 and its 200 day moving average is $253.44.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. Cencora had a return on equity of 328.62% and a net margin of 0.46%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business posted $3.80 earnings per share. As a group, research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, June 2nd. Stockholders of record on Friday, May 16th will be issued a $0.55 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $2.20 annualized dividend and a dividend yield of 0.78%. Cencora’s dividend payout ratio is currently 25.52%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. StockNews.com upgraded shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. JPMorgan Chase & Co. raised their target price on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Robert W. Baird lifted their target price on Cencora from $314.00 to $350.00 and gave the stock an “outperform” rating in a report on Thursday. Wells Fargo & Company increased their price target on Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a report on Friday, March 14th. Finally, UBS Group lifted their price objective on shares of Cencora from $298.00 to $335.00 and gave the company a “buy” rating in a research note on Tuesday, April 29th. Two analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Cencora has a consensus rating of “Moderate Buy” and a consensus target price of $301.18.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.